• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Tandem stock sinks after hours on Q3 misses, lowered guidance

November 1, 2023 By Sean Whooley

Tandem Diabetes Care updated logoTandem Diabetes Care (Nasdaq:TNDM) shares took a massive hit after hours today on third-quarter results that missed the consensus forecast.

Shares of TNDM fell nearly 20% at $14.27 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day up 1.1%.

The San Diego-based automated insulin delivery technology developer posted losses of $32.96 million. That equals 51¢ per share on sales of $185.6 million for the three months ended Sept. 30, 2023.

Tandem recorded a 32.7% bottom-line gain while remaining in the red on a sales decline of 9.3%.

The company’s losses per share fell 17¢ short of Wall Street expectations. Sales also fell shy of the forecast for $192.7 million in revenue.

Shortfalls in performance weren’t entirely unexpected, though. Tandem said last quarter that updates to its portfolio and reduced visibility on sales for the near future could hinder performance.

Highlights in the quarter included an 11% increase in the worldwide installed base compared to the same period a year ago. Tandem also announced positive data for its t:slim X2 system and commenced a limited U.S. launch of its new Mobi insulin patch pump.

“In this transitional year, we are focused on bringing the benefits of our #1 rated automated insulin delivery system to more people living with diabetes worldwide, providing customer care excellence and advancing our scalability initiatives,” said John Sheridan, Tandem president and CEO. “There is a large and growing opportunity for Tandem’s technology to drive greater use of automated insulin delivery worldwide, and we are advancing our efforts to expand this adoption through our near-term portfolio of diabetes solutions.”

Tandem lowers guidance again

Last quarter, due to additions to its portfolios and expected disruption ahead, Tandem amended its guidance for the full year. At the end of the first quarter, the company projected GAAP revenues ranging between $885 million and $900 million.

In the second quarter, Tandem said it expects non-GAAP sales to reach at least $785 million for the year ending Dec. 31, 2023.

Today, the company lowered expectations again. It now projects non-GAAP sales to total at least $765 million. Adjusted EBITDA margin is estimated to be at least breakeven as a percent of sales. Tandem did reaffirm its U.S. guidance for non-GAAP sales of at least $575 million.

“We are reaffirming our U.S. guidance, which is largely based on strong t:slim X2 renewal purchases and supply ordering trends. Our adjusted baseline expectations outside the U.S. factors in new disruption reported by our distribution partners in key markets and relates to the timing and process for new product launches,” said Leigh Vosseller, EVP and CFO. “We continue to yield positive results from our cost-saving initiatives, which is reflected in our reaffirmed margin expectations, as we focus on executing against our growth opportunity with efficiency and discipline.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Technology, Wall Street Beat Tagged With: Tandem Diabetes Care

IN CASE YOU MISSED IT

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Glucotrack can proceed with long-term glucose monitor study in Australia
  • Dexcom promotes Jake Leach to president role
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS